A
Axol Bioscience
Sells live human cell cultures and provides services such as genome editing to researchers
About Axol Bioscience
Axol Bioscience is a provider of human induced pluripotent stem cell (iPSC) technology for drug discovery and research. The company specializes in the manufacturing of iPSC-derived cells, offering a range of products including neurons, neuroinflammatory cells, muscle cells, and cardiac cells.
Axol Bioscience serves the drug discovery and screening markets, with a focus on neuroscience, immune cell, and cardiac modeling. Its clients are likely pharmaceutical and biotechnology companies, as well as academic and research institutions. The company's business model revolves around providing high-quality, functional iPSC-derived cells and related services to support the development of more human-relevant in vitro disease models. This helps researchers to better understand diseases and develop new treatments. The recent acquisition of Phenocell SAS has expanded Axol's iPSC-derived cell models and service offerings, particularly in the areas of ophthalmology and dermatology.
Source: Dealroom company dataAt a glance
- Founded
- 2013
- Headquarters
- Cambridge, United Kingdom
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Calculus Capital
Series A1 investor entered at this stage
Syndicate Room
Series B and later2 investors entered at this stage
- BPBroadOak Capital Partners
Roslin Foundation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Axol Bioscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Axol Bioscience on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.